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Abstract: This study was performed to investigate the relationship between patients’ activity and
function levels and the incidence of preoperative deep venous thrombosis (DVT) prior to total hip
arthroplasty (THA). We retrospectively reviewed 500 patients admitted for primary or revision THA
from July 2014 to October 2018. The diagnosis of DVT was confirmed using Doppler ultrasonography
1 month before THA. The patients’ activity and hip function were evaluated using several clinical
scores: the Harris Hip Score (HHS), Oxford Hip Score (OHS), University of California Los Angeles
(UCLA) activity score, and visual analog scale (VAS) score. Those scores and the medical history
were examined for correlations with preoperative DVT using univariate and multivariate models.
Univariate regression analysis showed that older age, current steroid use, anticoagulant use, a history
of DVT, collagen disease, a lower UCLA activity score, and a lower OHS were associated with an
elevated risk of preoperative DVT. The multivariate analyses showed that a higher UCLA activity
score (odds ratio (OR): 0.0049–0.012) and higher OHS (OR: 0.0012–0.0088) were associated with
a lower risk of preoperative DVT in each model. Age (OR: 1.07 in both models), current steroid
use (OR: 9.32–10.45), and a history of DVT (OR: 27.15–74.98) were associated with a higher risk of
preoperative DVT in both models. Older age, current steroid use, a history of DVT, a lower UCLA
activity score, and a lower OHS were risk factors for preoperative DVT before THA, even when
controlling for potential confounders. Patients exhibiting low activity and low function levels were
more likely to have DVT, even before surgery.
Keywords: deep venous thrombosis; total hip arthroplasty; University of California Los Angeles
activity score; Oxford Hip Score; preoperative deep venous thrombosis
1. Introduction
Deep venous thromboembolism (DVT) is still a common complication after hip arthroplasty and
can lead to pulmonary thromboembolism (PTE), although recent reviews have shown a significant
decrease in the incidence of fatal PTE after total hip arthroplasty (THA) [1,2]. According to the
American College of Chest Physicians’ evidence-based clinical practice guideline, hip surgery itself is a
risk factor for DVT [3]. If patients undergoing THA have DVT before the surgery, the risk of extension
of the thrombus and fatal PTE could be higher. Because patients with hip disability tend to be less
active, physicians should be aware of the possibility that patients might already have DVT, even before
the arthroplasty. Only a few studies have investigated the incidence of and risk factors for preoperative
DVT [4,5], and these studies showed that the prevalence of DVT prior to THA ranged from 5% to 12%.
J. Clin. Med. 2020, 9, 1257; doi:10.3390/jcm9051257 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 1257 2 of 11
To avoid critical complications associated with significant mortality, it is essential to determine the risk
factors for DVT in patients with hip disability undergoing THA.
Several risk factors for DVT after THA have been reported, including age [6–13],
female sex [7–11,13–16], a higher body mass index (BMI) [6,17], malignancy [6,7,11], and congestive
heart disease [6,9,11,13]. Bed rest [18] and immobilization [19,20] are also potential risk factors for
DVT; however, no studies have quantified the activity level and evaluated the effect of the activity
level on the risk of DVT.
Several scoring tools are used to evaluate the activity of patients with hip disease. The Oxford Hip
Score (OHS) is a patient-reported outcome measurement designed to evaluate hip function and pain.
This score has been proven to be reliable and valid and has been used in many clinical trials since its
introduction in 1996 [21,22]. The University of California Los Angeles (UCLA) activity score is another
widely used clinical measurement tool. This score is derived from a 10-point activity scale that evaluates
patient activity based on 10 descriptive activity levels, ranging from wholly inactive and dependent
(level 1) to regular participation in impact sports, such as jogging or tennis (level 10) [23]. The UCLA
activity score reportedly has the strongest correlation with other patient activity measurements, has the
highest reliability, and is the most effective activity rating scale for patients undergoing total hip and
knee arthroplasty [24]. The Harris Hip Score (HHS) is one of the most commonly used clinical-based
outcome measures and consists of pain, function, and range-of-motion components. Because these
measurements were designed for similar purposes, they show significant correlations (OHS and
HHS [25,26], UCLA and HHS [24,27,28], and UCLA and OHS [24,29]).
This study was performed to determine whether clinical measurements of patient activity and
function are associated with the risk of DVT prior to THA.
2. Patients and Methods
This was a retrospective study of primary and revision THAs performed from July 2014 to October
2018. During this period, patients undergoing primary or revision THA were subjected to preoperative
ultrasound examination for the detection of DVT. All patients provided informed consent, and the
study protocol was approved by the institutional review board of our hospital (#E884-2, approved on
19 May 2014). In total, 507 primary and revision THAs were performed at our institute during the study
period. Exclusion criteria were acute trauma (fracture) and symptomatic DVT at the time of surgery.
Three primary THAs performed for femoral neck fractures and four revision THAs performed for
periprosthetic fractures were excluded from this study. There were no patients who had symptomatic
DVT at the time of the index surgery.
Therefore, 500 THAs (425 primary THAs and 75 revision THAs) were included in the study.
The reason for the index THA was secondary osteoarthritis (OA) due to developmental dysplasia
in 249 cases, avascular necrosis of the femoral head in 82 cases, primary OA in 71 cases, rapidly
destructive coxarthrosis in 12 cases, rheumatoid arthritis in 6 cases, post-traumatic OA in 4 cases, and
OA secondary to infection in 2 cases. The reason for the index revision THA was aseptic loosening in
55 cases, infection in 9 cases, migration of the bipolar head into the acetabulum in 6 cases, and recurrent
dislocation in 5 cases. Fifty-one patients were taking one or more anticoagulants for the treatment
or prevention of myocardial infarction (13 cases), cerebral infarction (10 cases), atrial fibrillation (Af)
(7 cases), arrhythmia other than Af (2 cases), valvular heart disease (4 cases), and unknown reasons
(15 cases).
For the evaluation of patient activity and hip function, preoperative clinical assessments were
performed using the HHS, UCLA activity score, and OHS. The OHS was calculated according to the
modified scoring system, in which each question was scored from 0 to 4, with 4 representing the
best outcome or fewest symptoms. The overall score ranged from 0 to 48, with 48 being the best
outcome. The patients rated the pain intensity of the affected hip joint using the VAS, which ranged
from 0 (no pain) to 10 (worst imaginable pain). These clinical scores were obtained 1 month before
THA. We considered the following patient-related covariates: age, sex, BMI, a history of major surgery,
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a history of major surgery within the last 12 months, a known history of DVT, current steroid use,
administration of anticoagulants, smoking status, and the presence of comorbidities (congestive heart
failure (CHF), Af, diabetes mellitus (DM), collagen disease, or malignancy). Major surgery was defined
as surgery requiring anesthesia (general, orthopedic, neurologic, or gynecologic surgery), as reported
in a previous study [30]. Before the arthroplasty, patients were asked by the surgeon and a nurse
independently about their history of major surgery and the presence of comorbidities. All patients
underwent ultrasonography approximately 1 month prior to THA. Experienced clinical technicians
blind to the patients’ backgrounds and clinical measurements performed all examinations using
Doppler ultrasonography (Aplio 300, 500, or i800; Canon Inc., Tokyo, Japan).
Statistical Analysis
Differences in proportions were calculated by the chi-square test. Differences in means were
calculated by the Wilcoxon test to compare two groups. Probability values of <0.05 were considered
significant. In the univariate regression, the dependent variable was preoperative DVT and the
independent variables were age, sex, BMI, current steroid use, current anticoagulant use, smoking
status, a history of DVT, a history of major surgery, a history of major surgery in the last 12 months, the
presence of comorbidities (Af, CHF, DM, collagen disease, or malignancy), and preoperative clinical
measurements (HHS, OHS, UCLA activity score, and VAS score). To examine the presence of potential
multicollinearity in the following multivariate logistic analysis, the correlation among clinical scores
was tested using the Spearman rank correlation coefficient.
In the multivariate logistic regression analyses, the dependent variable was preoperative DVT
and the independent variables were demographic parameters and clinical measures reaching a
significance level of p < 0.05 in the univariate analysis. To evaluate the presence of multicollinearity,
the variance inflation factors for the selected variables were examined in each model. Receiver
operating characteristic (ROC) curves were used to examine the relations between the true positive
rate (sensitivity) and false positive rate (1 − specificity) and the areas under the ROC curve (AUC). The
Youden index (sensitivity + specificity − 1) was used to determine the optimal predictive cutoffs for
the clinical scores that showed significant relevance for the preoperative DVT risk.
All statistical analyses were performed using JMP Pro 14 software (SAS Institute, Cary, NC, USA).
3. Results
The patients’ demographic data are shown in Table 1. DVT was detected in 26 patients (5.2%)
before the index THA, all of which were asymptomatic. Proximal DVT was found in nine cases (six in
the femoral vein and three in the popliteal vein) and distal DVT (in calf veins) was found in 17 cases.
When DVT was found, the surgeon consulted with cardiologists and the cardiologists decided whether
an anticoagulant should be administered for each case. For the patients who had proximal DVT, an
anticoagulant was newly started before the index surgery in four cases. No anticoagulant was used
before surgery in two cases. The remaining three cases had been taking anticoagulants before the
ultrasound screening and they continued the drug after the detection of DVT. For the patients with
distal DVT, an anticoagulant was newly administered before THA in seven cases. No anticoagulant
was used before THA in eight cases. The remaining two cases continued taking the anticoagulant they
had been taking before the screening. The average age in the DVT group was significantly higher than
that in the no-DVT group (70.5 vs. 64.5 years, p = 0.0083). The DVT and no-DVT groups contained
24 (92.3%) and 385 (81.2%) women, respectively (p = 0.12). The mean BMI was 23.6 ± 4.0 kg/m2
(range, 18.2–32.2 kg/m2) in the DVT group and 24.3 ± 4.2 kg/m2 (range, 12.2–41.8 kg/m2) in the no-DVT
group (p = 0.63). Overall, 54 patients were currently using corticosteroids. The mean daily dose among
these 54 patients was 7.5 ± 4.9 mg (range, 1–20 mg). Ten patients (38.5%) in the DVT group, but
only 44 (9.3%) in the non-DVT group, were currently taking steroids; the proportion was significantly
higher in the DVT group (p < 0.0001). Twenty patients (76.9%) in the DVT group and 327 (69.0%) in
the no-DVT group had a history of major surgery (p = 0.22). When the history of major surgery was
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limited to 12 months prior to the index THA, the difference between the two groups was more marked
(26.9% vs. 13.3%). More patients in the DVT group tended to have a history of major surgery within
the last 12 months prior to the index THA, although the difference was not significant (p = 0.053).
Significantly more patients had a history of DVT in the DVT group than in the no-DVT group
(23.1% vs. 1.1%, p < 0.0001). Among the comorbidities, collagen disease was present in more patients
in the DVT group than in the no-DVT group (p = 0.023).
Table 1. Demographics of each group.
Variables Overall DVT No DVT p Value #
n 500 26 474
Sex
Male 91 2 89 0.12
Female 409 24 385












Current steroid use 54 10/26 44/474 <0.0001
Previous DVT history 11/500 6/26 5/474 <0.0001
Current anticoagulant use 51/500 6/26 45/474 0.026
Atrial fibrillation 15/500 1/26 14/474 0.80
Congestive heart failure 16/500 1/26 15/474 0.85
Major surgery 347/500 20/26 327/474 0.22
Major surgery within last 12 months 70/500 7/26 63/474 0.053
Diabetes mellitus 54/500 3/26 51/474 0.9
Collagen disease 55/500 7/26 48/474 0.023
Malignancy 78/500 3/26 75/474 0.55
Current smoking 36/500 1/26 35/474/ 0.50
Data are shown as the number of patients or the mean ± standard deviation (range). DVT: deep venous thrombosis
and BMI: body mass index. # Comparison of the presence and absence of preoperative DVT.
The breakdown of collagen diseases in each group is shown in Table 2. Significantly more
patients were under the administration of anticoagulants in the DVT group than in the no-DVT group
(23.1% vs. 9.5%). There was no difference in the incidence of DM, Af, CHF, or malignant disease
between the DVT and no-DVT groups. The percentage of current smokers was not significantly
different between the DVT and no-DVT group.
Table 2. Breakdown of collagen disease in each group.





Rheumatoid arthritis 23 2 21
Systemic lupus erythematosus 15 2 13
Dermatomyositis 8 1 7
Systemic sclerosis 3 3 0
Sjögren syndrome 3 0 3
Polymyalgia rheumatica 2 0 2
Polyarteritis nodosa 1 0 1
Adult Still’s disease 1 0 1
Behçet’s disease 1 0 1
Eosinophilic granulomatosis with polyangiitis 1 0 1
DVT: deep venous thrombosis.
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The clinical scores are shown in Table 3. Hereafter, the score and scale are given as the mean ±
standard deviation (range). The mean UCLA activity score was 2.64 ± 0.91 (2–5) in the DVT group and
3.75 ± 1.33 (1–8) in the no-DVT group (p < 0.0001). The mean OHS was 22.50 ± 12.32 (1–45) in the DVT
group and 29.73 ± 9.97 (1–48) in the no-DVT group (p = 0.006). The VAS score was higher in the DVT
group (6.88 ± 2.50 (0–10)) than in the no-DVT group (6.04 ± 2.82 (0–10)); however, the difference was
not significant (p = 0.21). The difference in the HHS between the DVT group (50.9 ± 17.79 (17.0–84.1))
and no-DVT group (52.66 ± 16.04 (5.7–99.6)) was also not statistically significant (p = 0.55).
Table 3. Clinical measurement scores for each group.
Variables Overall DVT No DVT p Value #
Oxford Hip Score 29.4 ± 10.2 22.5 ± 12.3 29.7 ± 10.0 0.0060
Harris Hip Score 52.6 ± 16.1 50.9 ± 17.8 52.7 ± 16.0 0.55
UCLA activity score 3.69 ± 1.34 2.64 ± 0.91 3.75 ± 1.33 <0.0001
VAS 6.08 ± 2.81 6.88 ± 2.50 6.04 ± 2.82 0.21
DVT: deep venous thrombosis, UCLA: University of California Los Angeles, and VAS: visual analog scale.
# Comparison of the presence and absence of preoperative DVT.
Because hip clinical scores reportedly have strong correlations with one another [24–29], the
correlation between each combination of the four clinical measurements (UCLA activity score, OHS,
HHS, and VAS score) was tested using Spearman’s rank correlation coefficient. The p-value and
Spearman’s rank correlation coefficient for each combination are shown in Tables 4 and 5, respectively.
All six combinations of the four clinical measurements (UCLA activity score, OHS, HHS, and VAS
score) had a statistically significant correlation. All combinations except the UCLA activity score and
VAS score (coefficient = −0.14) had an absolute coefficient value of 0.3 to 0.6, which is considered a
moderate correlation.
Table 4. Probability (p) value for the correlation of each combination of clinical measurements.
UCLA OHS HHS VAS
UCLA <0.0001 <0.0001 <0.0001 0.0039
OHS <0.0001 <0.0001 <0.0001
HHS <0.0001 0.0032
VAS <0.0001
OHS: Oxford Hip Score, HHS: Harris Hip Score, UCLA: University of California Los Angeles, and VAS: visual
analog scale.
Table 5. Spearman rank correlation coefficient for each combination of clinical measurements.
UCLA OHS HHS VAS
UCLA 1.0 0.34 0.43 −0.14
OHS 1.0 0.42 −0.60
HHS 1.0 −0.31
VAS 1.0
OHS: Oxford Hip Score, HHS: Harris Hip Score, UCLA: University of California Los Angeles, and VAS: visual
analog scale.
A multivariate logistic regression analysis was performed with two different models: regression
with parameters reaching a significance of p < 0.05 in the univariate analysis (i) with the OHS as
the representative clinical measurement and (ii) with the UCLA activity score as the representative
clinical measurement. This was performed to avoid potential multicollinearity between the OHS
and UCLA activity score, which was implied in Tables 4 and 5 and shown in previous literature [24],
demonstrating a significant correlation between the OHS and UCLA activity score (r = 0.48, p < 0.0001).
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In Model 1, age, a history of DVT, current steroid use, and the OHS were significantly correlated
with preoperative DVT (Table 6). In Model 2, age, a history of DVT, current steroid use, and the UCLA
activity score were significant risk factors for preoperative DVT (Table 7). Age, a history of DVT, and
current steroid use were significant risk factors for preoperative DVT in both models, and the UCLA
activity score and OHS were significantly correlated with preoperative DVT in each model when
involved as an independent variable.
Table 6. Multivariate logistic regression analysis using two parameters reaching p < 0.05 in univariate
testing with OHS as a representative clinical measurement.
Variables Odds Ratio 95% CI p Value VIF
OHS 0.95 0.91–0.99 0.031 1.02
Age 1.07 1.03–1.12 0.00056 1.12
Previous history of DVT 27.15 3.31–222.53 0.0021 1.18
Current anticoagulant use 0.48 0.09–2.63 0.39 1.20
Collagen disease 0.93 0.19–4.64 0.93 1.60
Current steroid use 10.45 2.31–47.34 0.0023 1.67
OHS: Oxford Hip Score, DVT: deep venous thrombosis, CI: confidence interval, and VIF: variance inflation factor.
Table 7. Multivariate logistic regression analysis using two parameters reaching p < 0.05 in univariate
testing with the UCLA activity score as a representative clinical measurement.
Variables Odds Ratio 95% CI p Value VIF
UCLA activity score 0.49 0.28–0.84 0.0099 1.16
Age 1.07 1.02–1.12 0.0027 1.27
Previous history of DVT 74.98 8.54–658.18 <0.0001 1.17
Current anticoagulant use 0.34 0.056–2.06 0.24 1.20
Collagen disease 1.03 0.23–4.68 0.97 1.55
Current steroid use 9.32 2.14–40.68 0.0030 1.69
UCLA: University of California Los Angeles, DVT: deep venous thrombosis, CI: confidence interval, and VIF:
variance inflation factor.
The mean UCLA activity score in patients with proximal DVT was 2.5 ± 0.5, whereas that in
patients with distal DVT was 2.7 ± 1.0. The difference was not significant (p = 0.69). There was no
significant difference between the proximal DVT group and distal DVT group in HHS (46.8 ± 12.7 vs.
53.5 ± 20.2, p = 0.35), or in OHS (21.9 ± 9.0 vs. 22.9 ± 14.2, p = 0.78).
The ROC curves are shown in Figure 1. The AUCs (95% confidence interval) for the UCLA activity
score and OHS were 0.755 (0.645–0.840) and 0.673 (0.536–0.786), respectively. The optimal predictive
cutoff for the UCLA activity score was 2 (sensitivity, 56.0%; specificity, 83.3%). Its positive (PPV) and
negative (NPV) predictive values were 15.7% and 94.7%, respectively. Its Youden Index was 0.393.
The optimal predictive cutoff for OHS was 22 (sensitivity, 54.5%; specificity, 76.6%; PPV, 10.4%; NPV,
97.1%). Its Youden Index was 0.312 (Table 8).
Table 8. The diagnostic value of the UCLA activity score and OHS.
Variables AUC YoudenIndex
Predictive
Cutoff Sensitivity Specificity PPV (%) NPV (%)
UCLA activity score 0.755 0.393 2 56.0 83.3 15.7 94.7
OHS 0.673 0.312 22 54.5 76.6 10.4 97.1
UCLA: University of California Los Angeles, OHS: Oxford Hip Score, AUC: area under the curve, PPV: positive
predictive value, and NPV: negative predictive value.
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4. Discussion
In the present study, 5.2% of the patients who were scheduled for THA had DVT, even before the
surgery. This proportion is in good accordance with those of previous studies (5.8%–12.3%) [4,5]. A few
reports have focused on preoperative DVT before other types of surgery. Akeda et al. [31] reported that
preoperative DVT was identified using a Doppler ultrasound in nine (4.3%) of 209 patients undergoing
spinal surgery. In another study, preoperative DVT was identified using a Doppler ultrasound in
25 (3.8%) of 654 patients undergoing surgery for gynecologic malignancy [32].
Older age is a predictor of preoperative DVT after THA [6–13] and before THA [5]. Our results
also demonstrated that older patients were significantly more likely to have DVT before THA.
Although a high BMI of >30 kg/m2 has been associated with a higher risk of DVT after THA [6,17]
and PTE after THA [33], we found no correlation between BMI and preoperative DVT. Likewise, two
other studies also showed no significant correlation between a high BMI and preoperative DVT [4,5].
Because the average BMI in the present study and the two above-mentioned studies was relatively low
(23–24 kg/m2), a possible explanation is that the studies contained too few patients with obesity to
examine the effect of excess body weight on the incidence of DVT. A larger number of patients with
obesity should be evaluated to more fully examine the effect of a high BMI.
Corticosteroid use is reportedly associated with DVT after surgery [34–36]. In the present study,
corticosteroid use significantly increased the risk of DVT, even before surgery.
The effect of DM on the risk for DVT after THA has been discussed in several studies. In their
meta-analysis of five studies, Zhang et al. [37] showed no correlation between DM and postoperative
DVT (odds ratio (OR): 1.02, p = 0.88). We also found no significant correlation between a history of DM
and the risk of DVT before THA.
Some authors have referred to malignancy as a significant risk factor for postoperative DVT after
THA [6,7,11], whereas others have shown no significant difference between malignancy and DVT,
providing an OR of 1.00 (0.72–1.39) [10] and 1.00 (0.32–3.11) [16]. In the present study, a history of
malignancy was not associated with preoperative DVT; however, we could not divide patients with
active and inactive malignancies because it was difficult to determine the exact stage of the tumor or
the recurrence only from the medical records in our institute.
Patients with a history of DVT have a higher risk of postoperative DVT after THA [6,9,10]. The
present study also indicated that a history of DVT was significantly correlated with an increased risk
of preoperative DVT before THA. Although no previous studies have demonstrated an increased risk
of preoperative DVT prior to THA for patients with a known history of DVT, a history of DVT would
understandably be a predictor of preoperative DVT.
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Some studies have shown that CHF was associated with an increased risk of postoperative
DVT after arthroplasty [9,11,13], whereas Beksac et al. [6] reported no correlation between CHF and
postoperative DVT. In the present study, CHF was not a predictor of preoperative DVT. However,
whether Af is associated with the risk of postoperative DVT has not been rigorously studied. Previous
studies that did not focus on the postoperative period demonstrated that Af was associated with an
increased risk of DVT [38,39]. Our results showed no association between Af and preoperative DVT.
However, only 16 patients had CHF and 15 had Af. It would be difficult to draw a conclusion regarding
CHF and Af as risk factors for preoperative DVT in this cohort.
Conclusions regarding the effect of anticoagulants on the risk of preoperative DVT would also
be difficult to draw in this study. While anticoagulant use was associated with an increased risk of
DVT in the univariate model, the association was not significant in the multivariate models. This
was unexpected because anticoagulants themselves are expected to prevent DVT. Most patients with
a history of DVT might have been taking anticoagulants to prevent the recurrence or expansion of
DVT, which could have strongly affected the association between anticoagulant use and DVT risk in
this study.
A history of major surgery is also a reported risk factor for DVT [4,30]. In this study, we included
a history of major surgery itself and major surgery within the last 12 months, because many patients
had undergone major surgeries a decade previously or could not recall exactly when the previous
major surgery was performed. As a result, a history of major surgery itself was not a risk factor, but
major surgery within the last 12 months tended to increase the risk of preoperative DVT (p = 0.053).
Hip clinical scores reportedly have strong correlations with one another [24–29]. Naal et al. [24]
showed a significant correlation between the UCLA activity score and OHS (r = 0.48, p < 0.0001) and
between the UCLA activity score and HHS (r = 0.56, p < 0.0001) among patients undergoing THA.
Beaulé et al. [27] found a strong correlation between the UCLA activity score and HHS with a Pearson
correlation coefficient of 0.57. Sechriest et al. [28] found that the UCLA score was positively correlated
with the HHS (r = 0.52, p = 0.001). Parsons et al. [26] reported that the OHS was correlated with the
HHS in their hip resurfacing series. Taking these correlations into account, we considered that if the
clinical scores were employed in the same multivariate regression, there must be a significant risk for
multicollinearity that should be avoided to strictly examine the effect of each hip score on the risk of
preoperative DVT. Therefore, we performed separate multivariate logistic regression analyses using
either the UCLA activity score or OHS as the representative clinical score, whereas in the univariate
analysis, both the UCLA activity score and OHS showed a significant correlation with the incidence of
preoperative DVT. The effect of clinical scores on the location of the thrombosis (proximal or distal)
was also examined; however, there was no association between those scores (UCLA activity score,
OHS, or HHS) and the location of thrombosis.
Collagen disease and current steroid use might also be confounding factors that are significantly
correlated with each other. However, because their variance inflation factors were <2, both of these
parameters were included in each multivariate model. While steroid use was significantly associated
with the presence of preoperative DVT, collagen disease was not an independent risk factor for
preoperative DVT.
This study had some limitations. First, the number of patients with preoperative DVT was
relatively small. If more patients had preoperative DVT, various other potential confounders could be
included in the analysis. Second, this cohort included various types of collagen diseases. Although
each disease might have had a different effect on the tendency to cause DVT, these diseases were
handled as a single disease group because of the small number of patients.
In conclusion, older age, current corticosteroid use, a history of DVT, a lower UCLA activity score,
and a lower OHS were significant risk factors for preoperative DVT in patients scheduled for THA.
The commonly used activity and hip function scales could help predict the risk of preoperative DVT.
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